Cikes M, Pettavel J
Schweiz Med Wochenschr. 1977 Nov 19;107(46):1645-55.
Predictive tests assisting in selection of breast cancer patients for endocrine therapy have been reviewed. Information gained from histologic sections, such as degree of the tumor differentiation, degree of elastosis, Barr-body count and the DNA content, are valuable predictors of prognosis and response to endocrine therapy. The length of time between mastectomy and recurrence of metastasis is an important factor in predicting response to ablative endocrine surgery. The presence of various enzymes in the tumor tissue, blood groups, immunologic competence, altered metabolism of tryptophan, urinary excretion of steroids and in vitro hormonal responsiveness of the tumor tissue have not been widely used as predictors of tumor response to endocrine therapy. The determination of hormone receptors in primary or metastatic breast tumors is at present the most reliable test in selecting breast cancer patients for endocrine therapy. Future developments in hormone receptor assay may provide a means of tailoring endocrine therapy to the individual patient.
已对有助于选择乳腺癌患者进行内分泌治疗的预测性检测进行了综述。从组织学切片获得的信息，如肿瘤分化程度、弹性组织变性程度、巴氏小体计数和DNA含量，是预后及内分泌治疗反应的重要预测指标。乳房切除术与转移复发之间的时间长度是预测对切除性内分泌手术反应的重要因素。肿瘤组织中各种酶的存在、血型、免疫能力、色氨酸代谢改变、类固醇的尿排泄以及肿瘤组织的体外激素反应性尚未广泛用作肿瘤对内分泌治疗反应的预测指标。目前，在选择乳腺癌患者进行内分泌治疗时，检测原发性或转移性乳腺肿瘤中的激素受体是最可靠的检测方法。激素受体检测的未来发展可能为根据个体患者量身定制内分泌治疗提供一种方法。
